ESR1: Teresa Swift

Individual Project

Single cell transcriptomics using the BD Rhapsody.

STACCATO Research

I will develop new workflows for the BD Rhapsody, supporting the single cell multiomic analysis being carried out by the STACCATO members.

Scientific Background

I have a degree in Biomedical Science from The University of Lincoln, UK, and Master of Science in Human Molecular Genetics from Imperial College London, UK, graduating in 2017.

During my master’s degree, I completed research under the supervision of Professor Julia Gorelik and Dr Ivan Diakonov at the Imperial Centre for Translational and Experimental Medicine, focusing on the intracellular signalling response of a newly discovered bile acid receptor in neonatal mammalian cardiac cells.

I gained experience in the bioproduction field working as a Scientist at Horizon Discovery prior to joining the STACCATO project. I was involved in the research and development of CHO host cell line, HD-BIOP3.

Publications

• Work from Teresa’s masters was included in a paper published in peer reviewed journal Scientific Reports.
• Four further publications are being prepared for submission to peer-reviewed journals in 2023.

Conferences

• Oral presentation: Matrix biology Ireland (MBI), Limerick, Ireland, 08. – 09.12. 2022.
  Altered transcriptomic signature characterises the post daratumumab treatment landscape of the bone marrow of a Multiple Myeloma patient.
• Poster presentation: British Society Immunology BSI, Liverpool, UK, 05.12.2022.
  Altered transcriptomic signature characterises the post daratumumab treatment landscape of the bone marrow of a Multiple Myeloma patient.
• Poster presentation: Irish Computational Biology and Genomics Symposium ICBG, Galway, Ireland, 01.12.2022.
  Single-cell transcriptomic analysis using BD Rhapsody™ Single-Cell Analysis System reveals the complexity of B-Cell Lymphoma microenvironment.
• Poster presentation: Matrix biology Ireland (MBI), Limerick, Ireland, 08. – 09.12.2022.
  Altered transcriptomic signature characterises the post daratumumab treatment landscape of the bone marrow of a Multiple Myeloma patient.